Use the navigation bar above to access articles and more discussions on this topic.
| Author |
Message |
    
Sarah Woodman
Member
Username: Meggles
Post Number: 29
Registered: 12-2004
| | Posted on Saturday, Aug 26, 2006 - 4:22 am: |   |
I'm wondering if anyone has heard of a new drug I've been told about that will prevent my mare coming into season. She has epilepsy that is related to her hormones and is currently on Regumate permanently. She now has a couple of seizures a year, as opposed to one every 18 - 20 days or so.
This drug (I'm not sure of the name) is apparently used in the US and was described to me as effectively a vaccine against GNRH which would in turn prevent the onset of oestrus. Apparently, the vaccination is required every two years and totally stops all oestrus activity. I'm told that I would probably not be able to breed from my mare in the future, but this isn't something thats an option for her anyway as falling over backwards when in foal could be disastrous.
Any ideas? I'm interested in what this is exactly, how successfully its been used and any possible side effects?
Thanks
Sarah |
Robert N. Oglesby DVM
Moderator
Username: Dro
Post Number: 16486
Registered: 1-1997
| | Posted on Monday, Aug 28, 2006 - 8:57 am: | |
Actually Sarah this is an old idea but I don't know anyone who manufacturers this vaccine. If you have information about such a product let us know. Here is a well conducted study that is 10 years old:
Aust Vet J. 1997 Sep;75(9):663-7.
Preliminary study of ovarian activity in fillies treated with a GnRH vaccine.
Tshewang U, Dowsett KF, Knott LM, Trigg TE.
Veterinary Science Farm, University of Queensland.
OBJECTIVE: To investigate the effects of two doses (200 and 400 mg) of a water-soluble gonadotrophin-releasing hormone vaccine on the ovarian activity of 2-year-old fillies. DESIGN: A controlled vaccination dose rate experiment. ANIMALS: Six 2-year-old Australian Stock Horse fillies were randomly allocated to three treatment groups; unvaccinated controls, those receiving 200 mg of the vaccine and those receiving 400 mg of the vaccine. RESULTS: Ovarian activity of the treated fillies was suppressed at the peak of breeding season while that of untreated controls continued normally. The control fillies displayed oestrous activity and behaviour. Suppression of ovarian activity occurred for 25 and 30 weeks in the 200 and 400 mg groups, respectively. These differences were not significant. Ovarian activity ceased 2 to 3 weeks after primary vaccination. Antibody titres were low (330) until after the booster immunisation when they rapidly peaked at 22,000 and 28,000 in the 200 mg and 400 mg groups, respectively. Plasma progesterone concentrations of the treated fillies remained below 3.18 nmol/L while GnRH was suppressed. The vaccine had no significant effect on plasma androstenedione concentrations. Recovery from the effect of the vaccine was associated with development of ovarian follicles, normal oestrous behaviour and ovulation. Three of the four treated fillies and one of the controls conceived during the next breeding season and foaled normally. All the treated fillies conceived and produced normal foals in the following two breeding seasons. CONCLUSION: Both dose rates suppressed ovarian function and prevented oestrous behaviour. These effects were reversible and the subsequent fertility of the vaccinated fillies was normal.
DrO |
